Role of Allopurinol in Prevention of Complications Related to Decompensated Cirrhosis of Liver

Cirrhosis, a leading cause of global mortality, progresses to life-threatening complications like ascites, hepatic encephalopathy, and hepatorenal syndrome. Oxidative stress and gut-liver axis dysfunction drive disease progression. Allopurinol, a xanthine oxidase inhibitor, has shown potential in reducing complications in cirrhosis, but robust clinical evidence is lacking. This study will evaluate allopurinol's efficacy in preventing complications in decompensated cirrhosis. This study aims to assess whether allopurinol reduces cirrhosis-related complications (ascites, variceal bleeding, hepatic encephalopathy, SBP, HRS-AKI) and improves MELD/CTP scores in Child-Pugh B/C cirrhosis patients. This study will select 54 patients with decompensated cirrhosis (Child-Pugh B/C). Patients aged 18-70 years, with any etiology of cirrhosis (viral, alcoholic, NAFLD). Patients with acute decompensation, allopurinol hypersensitivity, advanced renal impairment (CrCl \

Inclusion Criteria: * • Adult patients (age : 18-70 years) diagnosed with Decompensated cirrhosis of liver with any etiology of cirrhosis . * CTP score B or C . Exclusion Criteria: * • Patients with known hypersensitivity or allergy to allopurinol. * Patients with active HE or SBP or HRS-AKI or a history of any of these events within the last 4 weeks. * Patients with advanced renal impairment (e.g., creatinine clearance \